Chronic Hepatitis B Management
Patient Selection
- HBeAg-negative patients with HBV DNA >2,000 IU/mL and elevated ALT are considered for treatment, according to the American Association for the Study of Liver Diseases 1
- Patients receiving immunosuppressive therapy are at risk of HBV reactivation and require prophylactic antiviral therapy, as recommended by the National Comprehensive Cancer Network 2
Treatment Duration and Monitoring
- Treatment should be continued until HBeAg seroconversion and undetectable HBV DNA, and then for at least 12 additional months, based on evidence from the American Association for the Study of Liver Diseases 1
- Regular monitoring of HBV DNA every 3 months until undetectable, then every 3-6 months, and ALT monthly until normalized, then every 3 months, is essential for effective management, as recommended by the American Association for the Study of Liver Diseases 1
- The following monitoring schedule is recommended:
| Test | Frequency |
|---|---|
| HBV DNA | Every 3 months until undetectable, then every 3-6 months |
| ALT/AST | Monthly until normalized, then every 3 months |
| HBeAg/anti-HBe | Every 6 months in HBeAg-positive patients |
Treatment Options
- Pegylated interferon alfa-2a has a finite treatment duration of 48 weeks, with no resistance development, but is limited by side effects and lower response rates in patients with high HBV DNA and normal ALT, according to the American Association for the Study of Liver Diseases 1
- Lamivudine has a high risk of resistance with long-term therapy, as reported by the American Association for the Study of Liver Diseases 1
- Telbivudine has a moderate rate of resistance compared to entecavir and tenofovir, based on evidence from the American Association for the Study of Liver Diseases 1
- The following table summarizes the treatment outcomes at 48-52 weeks for HBeAg-positive patients:
| Agent | HBV DNA <60-80 IU/mL | ALT normalization | HBeAg seroconversion | HBsAg loss |
|---|---|---|---|---|
| PEG-IFN-2a | 14% | 41% | 32% | 3% |
| Entecavir | 67% | 68% | 21% | 2% |
| Tenofovir | 76% | 68% | 21% | 3% |
Prophylactic Antiviral Therapy
- Prophylactic antiviral therapy is essential for HBsAg-positive patients receiving immunosuppressive therapy, and should be started before or simultaneously with immunosuppression and continued for at least 6 months after discontinuation, as recommended by the National Comprehensive Cancer Network 2
- Mandatory antiviral prophylaxis with high barrier to resistance agents, such as entecavir (0.5 mg daily), tenofovir disoproxil fumarate (300 mg daily), or tenofovir alafenamide (25 mg daily), should be used to prevent HBV reactivation in patients receiving tofacitinib, according to the American Gastroenterological Association 6
- The following table summarizes the recommended first-line antiviral agents and dosages:
| Antiviral Agent | Dosage |
|---|---|
| Entecavir | 0.5 mg daily |
| Tenofovir disoproxil fumarate (TDF) | 300 mg daily |
| Tenofovir alafenamide (TAF) | 25 mg daily |
- Antiviral therapy should be started before or at the latest simultaneously with tofacitinib and continued for at least 6 months after discontinuation of tofacitinib to prevent delayed reactivation, as recommended by the American Society of Clinical Oncology 3
- Premature discontinuation of therapy can lead to hepatitis flares, and ALT levels should be monitored frequently (at least monthly for the first 3 months) after stopping antivirals, as recommended by the AASLD 3
- Regular monitoring of HBsAg, ALT, and HBV DNA every 3 months during therapy and up to 6 months after is recommended, and antiviral therapy should be initiated immediately if HBV reactivation occurs, according to the American Gastroenterological Association 6
- Coordinate care with a hepatologist to monitor patients receiving tofacitinib, as recommended by the American Society of Clinical Oncology 3
Screening and Prevention
- The American College of Gastroenterology and the Centers for Disease Control and Prevention recommend screening for HBV in individuals from high-prevalence areas, household contacts of HBV-infected persons, sexual partners of HBV-infected persons, men who have sex with men, injection drug users, healthcare workers with potential blood exposure, patients receiving immunosuppressive therapy, patients with HIV infection or other liver diseases, and patients on dialysis or with end-stage renal disease, as well as all pregnant women for HBsAg at first prenatal visit 8, 10
- The following table summarizes the recommended screening tests:
| Test | Population |
|---|---|
| HBsAg | Patients at risk of infection |
| anti-HBc | Patients at risk of infection |
| anti-HBs | Patients at risk of infection |
| HBeAg | Confirmed HBV infection |
| anti-HBe | Confirmed HBV infection |
| HBV DNA quantification | Confirmed HBV infection |
| Liver function tests | Confirmed HBV infection |
| Liver fibrosis assessment | Confirmed HBV infection |
- Pregnant women with high HBV DNA levels (>200,000 IU/mL) should receive antiviral prophylaxis with TDF starting at 24-28 weeks of gestation, as recommended by the American College of Obstetricians and Gynecologists (ACOG) 3
- The American Association for the Study of Liver Diseases recommends antiviral therapy for women with HBV DNA >10^6 IU/mL starting at 26-28 weeks of gestation through 4 weeks postpartum to prevent vertical transmission, and universal vaccination of all infants at birth, vaccination of unvaccinated children and adults at risk, and a three-dose schedule achieves protective antibody response in >90% of adults and >95% of adolescents 8, 10
Long-term Outcomes
- Long-term viral suppression with nucleos(t)ide analogues improves hepatic inflammation and fibrosis, preventing progression to decompensated cirrhosis and reducing (but not eliminating) the risk of hepatocellular carcinoma, as reported by the AASLD 4
- Successful antiviral therapy reduces but does not eliminate the risk of HCC development, with a strength of evidence rated as high 11, 12
- TAF has a high genetic barrier to resistance, with no documented resistance development through 8 years of treatment, according to Clinical and Molecular Hepatology 7
- The EASL defines resistance development as an increase in HBV DNA >1 log10 IU/ml from nadir, which requires prompt intervention with addition or switch to non-cross-resistant agent, with a strength of evidence rated as high 13